Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:4971
Name myelofibrosis
Definition A myeloid neoplasm that is located in the bone marrow which results in bone marrow being replaced by fibrous (scar) tissue.
Source DiseaseOntology.org
Alt Ids DOID:5737
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm myelofibrosis

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
JAK2 V617F N/A myelofibrosis not applicable detail...
IDH1 mutant N/A myelofibrosis not applicable detail...
IDH2 mutant N/A myelofibrosis not applicable detail...
DNMT3A mutant N/A myelofibrosis not applicable detail...
CBL mutant N/A myelofibrosis not applicable detail...
JAK2 V617F INCB053914 myelofibrosis predicted - sensitive detail...
JAK2 mutant N/A myelofibrosis not applicable detail...
TET2 mutant N/A myelofibrosis not applicable detail...
JAK2 V617F C220 myelofibrosis predicted - sensitive detail...
NRAS mutant N/A myelofibrosis not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01398462 Phase I CWP232291 Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients Completed USA 1
NCT01644110 Phase Ib/II Pomalidomide + Ruxolitinib Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF (POMINC) Active, not recruiting 1
NCT01787487 Phase II Azacitidine + Ruxolitinib Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm Recruiting USA 0
NCT02098161 Phase II LCL161 LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis Active, not recruiting USA 0
NCT02158858 Phase Ib/II CPI-0610 + Ruxolitinib CPI-0610 A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis Recruiting USA | CAN 7
NCT02251821 Phase II Fludarabine Tacrolimus Mycophenolate mofetil Busulfan Pacritinib Momelotinib Melphalan Methotrexate Ruxolitinib Cyclophosphamide JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis Recruiting USA 0
NCT02268253 Phase II Tagraxofusp-erzs Tagraxofusp (SL-401) in Patients With CMML or MF Recruiting USA | CAN 0
NCT02386800 FDA approved Ruxolitinib Panobinostat + Ruxolitinib CINC424A2X01B Rollover Protocol Recruiting 23
NCT02421354 Phase II Nivolumab Study of Nivolumab in Patients With Myelofibrosis Terminated USA 0
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated USA 1
NCT02493530 Phase I Ruxolitinib + Umbralisib TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea Active, not recruiting USA 0
NCT02528877 Phase I Fludarabine + Melphalan Ruxolitinib + Sirolimus + Tacrolimus Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis Withdrawn USA 0
NCT02530034 Phase I Hu8F4 Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Recruiting USA 0
NCT02530619 Phase I Alisertib Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia Active, not recruiting USA 0
NCT02564536 Phase I Decitabine + Pacritinib Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) Withdrawn 0
NCT02718300 Phase II Parsaclisib + Ruxolitinib A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis Active, not recruiting USA 0
NCT02966353 Phase II Ruxolitinib Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE) Completed CAN 10
NCT03042689 Phase I Regorafenib Study of Regorafenib in Patients With Advanced Myeloid Malignancies Active, not recruiting USA 0
NCT03065400 Phase II Pembrolizumab PD-1 Inhibition in Advanced Myeloproliferative Neoplasms Completed USA 0
NCT03136185 Phase II IMG-7289 IMG-7289 in Patients With Myelofibrosis Active, not recruiting USA 4
NCT03144687 Phase II Itacitinib + Ruxolitinib Itacitinib A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis Completed USA 2
NCT03165734 Phase II Lenalidomide Ruxolitinib Hydroxyurea Pacritinib Thalidomide A Phase 2/3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA) Recruiting USA | CAN 17
NCT03289910 Phase II Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Active, not recruiting USA 0
NCT03326310 Phase I Azacitidine + Selumetinib Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia Recruiting USA 0
NCT03373877 Phase I PU-H71 + Ruxolitinib Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis Terminated USA 0
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Recruiting USA 0
NCT03592576 Expanded access Navitoclax Expanded Access to Navitoclax Available 0
NCT03627403 Phase II Selinexor Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL) Recruiting USA 0
NCT03645824 Phase II Pacritinib Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) (HOVON134MF) Recruiting 2
NCT03662126 Phase II KRT-232 KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor Recruiting USA | CAN 10
NCT03755518 Phase III Fedratinib An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM) Recruiting USA | CAN 0
NCT03862157 Phase Ib/II Azacitidine + MLN4924 + Venetoclax Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting USA 0
NCT03886831 Phase I PRT543 A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies Recruiting USA 0
NCT03895112 Phase I AVID200 MPN-RC 118 AVID200 in Myelofibrosis Active, not recruiting USA 0
NCT03912064 Phase I Ipilimumab A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Recruiting USA 0
NCT03935555 Phase I PU-H71 Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib Recruiting USA 0
NCT03952039 Phase III Fedratinib An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2) Recruiting 16
NCT04041050 Phase I Navitoclax Navitoclax + Ruxolitinib A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm Recruiting USA 13
NCT04089449 Phase I PRT811 A Study of PRT811 in Participants With Advanced Solid Tumors, Gliomas and Myelofibrosis Recruiting USA 0
NCT04173494 Phase III Danazol Momelotinib A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM) Active, not recruiting USA | CAN 20
NCT04176198 Phase I TP-3654 A Study of Oral TP-3654 in Patients With Myelofibrosis Recruiting USA 0
NCT04279847 Phase I INCB057643 Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis Recruiting USA 2
NCT04281498 Phase II Enasidenib + Ruxolitinib Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation Recruiting USA | CAN 0
NCT04282187 Phase II Decitabine + Fedratinib Decitabine + Ruxolitinib Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms Recruiting USA 0
NCT04454658 Phase I ABBV-744 ABBV-744 + Navitoclax ABBV-744 + Ruxolitinib Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis Recruiting USA 14
NCT04468984 Phase III Navitoclax + Ruxolitinib Safety, Efficacy, and Assessment of Change in Spleen Volume Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2) Recruiting USA | CAN 27
NCT04472598 Phase III Ruxolitinib Navitoclax + Ruxolitinib Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (TRANSFORM-1) Recruiting USA | CAN 23
NCT04480086 Phase I Mivebresib + Navitoclax Mivebresib + Ruxolitinib Mivebresib Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis Active, not recruiting USA 4
NCT04485260 Phase Ib/II KRT-232 + Ruxolitinib An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib Recruiting USA 7
NCT04517851 Phase I Elotuzumab Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis Recruiting USA 0
NCT04551053 Phase III Parsaclisib + Ruxolitinib Ruxolitinib To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) Recruiting USA 18
NCT04551066 Phase III Ruxolitinib Parsaclisib + Ruxolitinib To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) Recruiting USA 16
NCT04576156 Phase III Thalidomide Danazol Hydroxyurea Imetelstat A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment Recruiting USA 26
NCT04603495 Phase III CPI-0610 + Ruxolitinib Ruxolitinib Study of CPI-0610 in Myelofibrosis (MF) (MANIFEST-2) Recruiting USA | CAN 10
NCT04629508 Phase II Itacitinib To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy. Recruiting USA 5
NCT04817007 Phase I BMS986158 + Ruxolitinib BMS986158 + CYC065 BMS986158 A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) Recruiting USA 5
NCT04878003 Phase II TL-895 KRT-232 Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naive Myelofibrosis Recruiting USA 6
NCT04955938 Phase I Enasidenib + Fedratinib Fedratinib + Ivosidenib A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms Recruiting USA 0
NCT05127174 Phase Ib/II Fedratinib Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms Recruiting USA 0